You are viewing the site in preview mode

Skip to main content

Table 2 One-year overall survival models utilized. From Left to write, the first two columns represent the two comparison populations for the survival analysis conducted. Following this, the matched population sizes and number of morality events in each comparison group are represented. Finally, the median survival time for each comparison group are represented followed by the hazard ratio comparing survival probability and its associated p-value. The hazard ratio with its associated 95% confidence interval below it (in parenthesis). Hazard ratios are reported relative to group 1 (ie Values greater than 1 suggest group 1 has increased 1 year mortality risk relative to group 2)

From: Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy

Analysis Conduced

Matched Population Sizes

Mortality Events (n)

Median Survival Time (days)

Hazard Ratio, (95% CI)

P-value

Group 1

Group 2

Group 1

Group 2

Group 1

Group 2

Myocarditis

Non- myocarditis

424

204

185

323

Majority alive

1.26,

(1.04- 1.54)

0.02

Pericarditis

Non- pericarditis

192

101

85

249

Majority alive

1.36,

(1.02- 1.81)

0.04

Tamponade

Non- tamponade

415

288

204

84

324

2.15,

(1.79- 2.57)

 < 0.01

Pericardial effusion

Non- pericardial effusion

3,756

1,928

1,542

266

Majority alive

1.49,

(1.39- 1.59)

 < 0.01

Pericarditis Disease

Non- pericardial disease

3,945

2,027

1,659

263

Majority alive

1.46,

(1.37- 1.56)

 < 0.001

Myocarditis

Pericarditis

144

69

75

267

249

0.97,

(0.70- 1.35)

0.87

Myocarditis

Pericardial Disease

376

184

191

289

251

0.95,

(0.77- 1.16)

0.60